TALKDESK
16.12.2021 11:02:14 CET | Business Wire | Press release
Talkdesk®, Inc. , the global customer experience leader for customer-obsessed companies, has been chosen by Travelopia , the world’s largest collection of specialist travel brands, as its contact centre solution provider. Talkdesk provided a flexible, scalable solution as this pioneer in specialty travel charted a new course to remote call center technology for its portfolio of independent brands operating across the globe.
Travelopia - the only travel brand of its kind in the world - is at the forefront of global travel for those wanting a distinctive experience. With primary headquarters in Crawley, England, the company supports a global network of hospitality professionals representing 23 independent travel brands offering more than 70 destinations, spanning 10 countries across all seven continents. The Travelopia portfolio is exclusively focused on specialist travel, and the company strives to deliver unique experiences - from exploring Canada’s Rideau Canal by boat to joining the ranks of those rare travellers who cross the Antarctic Circle to see the South Pole. Whether travelling around the world by private jet or exploring closer to home on bicycle, Travelopia helps cultivate the passions and interests of its more than 750,000 guests each year.
Talkdesk CX Cloud™ , an end-to-end customer experience solution, made the transition from on premises to remote contact centre operations much easier for the geographically diverse Travelopia network of sales agents responsible for helping guests with highly customised travel itineraries and complex customer support enquiries. Agents across multiple geographies could better manage their time, which reduced the number of missed guest calls. The Talkdesk solution offered robust analytics, and those deeper insights into customer data enabled agents to proactively suggest new, customised travel experiences for returning guests. The flexibility and scalability of remote contact centre operations allowed Travelopia to efficiently adapt to the rapidly changing travel market conditions over the last year, as well as lowered operating costs during a volatile time for the travel industry as a whole.
“One of the core values driving Travelopia forward is our constant pursuit of the ultimate customer experience for our guests to enrich their lives through travel. As part of that pursuit, we’re committed to reflect on and evolve our operational approach,” said Mark Beauchamp, technology director, Travelopia. “For our move to remote contact centre operations, we wanted an innovative, flexible solution with the best tools to delight our customers. The Talkdesk solution provides our global network of agents across the portfolio of Travelopia brands with the resources they need to provide a seamless customer journey for guests - from first contact with our sales team through to the conclusion of that world beating travel experience.”
“Customer experience has never been more important to the success of travel and hospitality brands as it is now. Travellers worldwide are making up for lost time and missed opportunities, and they will choose to partner with those companies that can deliver not only that once-in-a-lifetime adventure, but also an unforgettable customer service experience before, during, and after,” said Kieran King, chief customer officer, Talkdesk. “With the Talkdesk solution, Travelopia agents can provide customer experience as unique and meaningful as the extraordinary travel experiences they create. We’re proud to partner with Travelopia in achieving their customer experience goals.”
Additional Resources
- See Talkdesk recognized as a Leader in the Gartner 2020 Magic Quadrant for Contact Center as a Service
- Hear from customers about why they selected Talkdesk CX Cloud and the difference it has made in their contact centers
Social Networks
- Web: https://www.talkdesk.com/customer-community/
- Blog: https://www.talkdesk.com/blog/
- Twitter: https://twitter.com/Talkdesk
- LinkedIn: https://www.linkedin.com/company/talkdesk/
- Facebook: https://www.facebook.com/Talkdesk/
- Instagram: https://www.instagram.com/Talkdesk/
About Talkdesk
Talkdesk® is a global cloud contact center leader for customer-obsessed companies. We believe that better customer experiences start with AI. Our automation-first customer experience solutions optimize our customers’ most critical customer service processes. Our speed of innovation, deep vertical expertise, and global footprint reflect our commitment to ensuring that businesses everywhere can deliver better customer experiences across any industry and through any channel, resulting in higher customer satisfaction and accelerated business outcomes. Over 1,800 innovative companies around the world, including Acxiom, Fujitsu, Hunter Douglas, IBM, Trivago, Tuft & Needle, YMCA, and 2U partner with Talkdesk to deliver a better way to great customer experience. Learn more and request a demo at www.talkdesk.com .
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered ® trademarks of their respective holders. Use of them does not imply any affiliation or endorsement by them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
